Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects.
OBJECTIVE
The current study was designed to test the acute effects of dietary advanced glycation end products (AGEs) on endothelial function of diabetic and nondiabetic subjects.


METHODS
Flow-mediated dilation (FMD) of the brachial artery and serum levels of AGEs, plasminogen activator inhibitor 1 (PAI-1), vascular cell adhesion molecule 1 (VCAM-1), and glucose were assessed before and after a single oral AGE challenge (approximately 1.8 x 10(6) AGE units) in 44 diabetic and 10 nondiabetic subjects.


RESULTS
The diabetic patients had higher baseline levels of serum AGEs (P = 0.020), PAI-1 (NS), and VCAM-1 (P = 0.033) and lower baseline values of FMD compared with nondiabetic subjects (P = 0.032). Ninety minutes after a single oral AGE challenge, serum AGEs and PAI-1 levels increased and FMD decreased significantly in both healthy subjects (AGEs: 7.2 +/- 0.5 to 9.3 +/- 1 units/ml, P = 0.014; PAI-1: 5.4 +/- 0.4 to 6.8 +/- 0.4 ng/ml, P = 0.007; and FMD: 9.9 +/- 0.7 to 7.4 +/- 0.9%, P = 0.019) and diabetic subjects (AGEs: 10.5 +/- 0.7 to 14.2 +/- 1 units/ml, P = 0.020; PAI-1: 6.5 +/- 1 to 10 +/- 2 ng/ml, P = 0.030; and FMD: 5.4 +/- 0.4 to 4.0 +/- 0.3%, P = 0.032). Serum glucose and VCAM-1 levels remained unchanged.


CONCLUSIONS
Significant increases in serum AGEs can occur together with altered clinical measures of endothelial function in diabetic and nondiabetic subjects after a single modest AGE-rich beverage. Thus, repeated or chronic exposure to high AGE diets could over time lead to and/or accelerate vascular disease.
Uribarri
Jaime
J
Division of Nephrology, Department of Medicine, Mount Sinai School of Medicine, One Gustave Levy Pl., New York, NY 10029, USA. jaime.uribarri@mssm.edu
Stirban
Alin
A
Sander
Denise
D
Cai
Weijing
W
Negrean
Monica
M
Buenting
Cristina E
CE
Koschinsky
Theodore
T
Vlassara
Helen
H
D000284:Administration, Oral; D002318:Cardiovascular Diseases / Q000097:blood / Q000503:physiopathology; D003920:Diabetes Mellitus / Q000503:physiopathology*; D003925:Diabetic Angiopathies / Q000097:blood / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology* / Q000503:physiopathology; D017127:Glycation End Products, Advanced / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D006801:Humans; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D012016:Reference Values
D017127:Glycation End Products, Advanced; D017395:Plasminogen Activator Inhibitor 1